Dr David O'Reilly was appointed to the Management Board of British American Tobacco as Group Scientific and R&D Director, in January 2012. He graduated from Imperial College, London in 1991 with a Ph.D. in molecular virology. He continued to pursue this area of research when he joined Advanced Technologies Cambridge, a subsidiary of British American Tobacco, In recent years at BAT, O’Reilly has been a driving force behind the creation and growth of BAT’s multidisciplinary global R&D effort in consumer-led, science-based innovation in next-generation tobacco and nicotine products. He has also led the company’s programs in corporate social responsibility, tobacco harm reduction and scientific and public health policy and engagement. He is co-founder of the Global Tobacco and Nicotine Forum and Chairman emeritus of the GTNF Advisory Board.